The Alzheimer’s drug development pipeline for 2024 is bustling with activity, featuring 171 ongoing studies and 134 drugs in clinical trials. Notable treatments in the pipeline include donanemab and the first oral Alzheimer’s drug, ALZ-801. Donanemab, an anti-amyloid therapy, is expected to receive a decision from the FDA this year. Meanwhile, ALZ-801 aims to provide a more accessible treatment option by offering an oral medication instead of the traditional intravenous infusions.
These advancements are part of a broader effort to develop disease-modifying treatments that can slow cognitive decline and improve the quality of life for those affected by Alzheimer’s. The diversity of the pipeline and the innovative approaches being tested offer new hope to patients and their families.
Donanemab, which made headlines in 2023, works by targeting and removing amyloid plaques, a hallmark of Alzheimer’s disease. Clinical trials have shown that donanemab can significantly slow cognitive decline, especially when administered early in the disease’s progression. The FDA’s decision on donanemab is eagerly awaited, as it could mark a significant milestone in Alzheimer’s treatment.
ALZ-801 represents another exciting development. This oral medication targets the same amyloid plaques but offers the convenience of a pill, making it easier for patients to adhere to their treatment regimen. The drug’s manufacturer is expected to submit a new drug application to the FDA later this year, pending the final results of a Phase 3 clinical trial.
In addition to these treatments, there are numerous other drugs in various stages of development, each aiming to address different aspects of the disease. The focus on disease-modifying therapies, which target the underlying pathological changes in Alzheimer’s, represents a significant shift from symptomatic treatments to more effective long-term solutions.
For a comprehensive overview of the latest developments, visit the BrightFocus Foundation.
Sources:
